NCT04738292 2024-05-03Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)University of Wisconsin, MadisonPhase 2 Terminated11 enrolled 10 charts